Trial Profile
Multicenter, Randomized, Blinded, Two-period Cross-over Study to Assess the Effect of Glycopyrronium (44 Micrograms QD) Versus Tiotropium (18 Micrograms QD) on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 15 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Aug 2014 According to the European Clinical Trials Database record, status changed from not yet recruiting to recruiting.
- 28 Feb 2014 New source identified and integrated (UK Clinical Trials Register; UKCRN- 16277).